EP Patent

EP3659621A1 — Combination therapies for cancer

Assigned to Novartis AG · Expires 2020-06-03 · 6y expired

What this patent protects

Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.

USPTO Abstract

Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders.

Drugs covered by this patent

capmatinib-hydrochloride (CAPMATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: EP3659621A1
Jurisdiction: EP
Classification: —
Expires: 2020-06-03
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.